Naendrup, Jan-Hendrik
Steinke, Jonathan
Grans-Siebel, Judit
Koehler, Philipp
Böll, Boris http://orcid.org/0000-0002-6432-0981
Funding for this research was provided by:
Universitätsklinikum Köln
Article History
Accepted: 15 March 2023
First Online: 28 March 2023
Declarations
:
: BB received scientific grants and honoraria not related to the submitted manuscript from Noscendo, Novartis, Kite/Gilead, Miltenyi, Pfizer, Roche and Janssen & Janssen. PK reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC and University Hospital and LMU Munich; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited and Pfizer Pharma; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work. JHN, JS and JGS declare that they have no competing interests.
: Prior to the start of the study, approval was obtained by the local ethics committee (approval number 20-11729). Given the non-interventional retrospective nature of the study, no informed consent had to be obtained from the included patients.
: Not applicable.